PharmGKB and the International Warfarin Pharmacogenetics Consortium: the changing role for pharmacogenomic databases and single-drug pharmacogenetics
Open Access
- 10 March 2008
- journal article
- databases
- Published by Hindawi Limited in Human Mutation
- Vol. 29 (4) , 456-460
- https://doi.org/10.1002/humu.20731
Abstract
PharmGKB, the pharmacogenetics and pharmacogenomics knowledge base (www.pharmgkb.org) is a publicly available online resource dedicated to the dissemination of how genetic variation leads to variation in drug responses. The goals of PharmGKB are to describe relationships between genes, drugs, and diseases, and to generate knowledge to catalyze pharmacogenetic and pharmacogenomic research. PharmGKB delivers knowledge in the form of curated literature annotations, drug pathway diagrams, and very important pharmacogene (VIP) summaries. Recently, PharmGKB has embraced a new role—broker of pharmacogenomic data for data sharing consortia. In particular, we have helped create the International Warfarin Pharmacogenetics Consortium (IWPC), which is devoted to pooling genotype and phenotype data relevant to the anticoagulant warfarin. PharmGKB has embraced the challenge of continuing to maintain its original mission while taking an active role in the formation of pharmacogenetic consortia. Hum Mutat 29(4), 456–460, 2008.Keywords
Funding Information
- National Institutes of Health (NIH)
- National Institute of General Medical Sciences (NIGMS) (UO1GM61374)
This publication has 14 references indexed in Scilit:
- CYP4F2 genetic variant alters required warfarin doseBlood, 2008
- The new mutation theory of phenotypic evolutionProceedings of the National Academy of Sciences, 2007
- Genetic influences on the response to warfarinCurrent Opinion in Hematology, 2006
- The Pharmocogenomics of Warfarin: Closing in on Personalized MedicineMolecular Interventions, 2006
- A case study of acenocoumarol sensitivity and genotype‐phenotype discordancy explained by combinations of polymorphisms in VKORC1 and CYP2C9British Journal of Clinical Pharmacology, 2006
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseNew England Journal of Medicine, 2005
- VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulationThrombosis and Haemostasis, 2005
- Identification of the gene for vitamin K epoxide reductaseNature, 2004
- Integrating genotype and phenotype information: an overview of the PharmGKB projectThe Pharmacogenomics Journal, 2001
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999